Sarepta Therapeutics Inc expected to post earnings of 26 cents a share - Earnings Preview

Sarepta Therapeutics

03/08/2026 21:32

Sarepta Therapeutics Inc SRPT.OQ SRPT.O is expected to  show a fall in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Cambridge Massachusetts-based  company is expected to report a 40.4% decrease in revenue to $364.343 million from $611.09 million a year ago, according to the mean estimate from 20 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Sarepta Therapeutics Inc is for earnings of 26 cents per share. 
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 9 "strong buy" or "buy," 12 "hold" and 6 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Sarepta Therapeutics Inc is $20.00, about 34.6% above its last closing price of $14.86
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
1.27
0.99
2.88
Beat
190.4
Dec. 31 2026
-1.29
-1.23
-3.93
Missed
-219.3
Sep. 30 2025
-0.89
-0.82
-0.01
Beat
98.8​
Jun. 30 2025
0.70
0.75
1.89
Beat
151.8
​​Mar. 31 2025
-0.48
-0.95
-4.60
Missed
-385.8
Dec. 31 2024
2.05
1.90
1.50
Missed
-20.9​
Sep. 30 2024
0.01
-0.13
0.34
Beat
353.7
Jun. 30 2024
-0.01
0.01
0.07
Beat
1,198.7
This summary was machine generated August 3 at 20:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)